Physician profile
Amy Su
NPI 1922674290
$4,635.40
in general payments reported to CMS, 2019-2025
32 companies · $1,785 in 2025
The $1,785 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $505 · 2023: $888 · 2024: $1,457 · 2025: $1,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,098 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,097.88 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $514.76 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $461.88 | 2025 | |
| Pfizer INC. | $373.85 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $305.41 | 2022-2024 | |
| Amgen INC. | $257.84 | 2022-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $252.98 | 2022-2024 | Optimizer, Optimizer |
| Merck Sharp & Dohme LLC | $235.39 | 2022-2024 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $197.03 | 2023-2024 | Jardiance |
| Janssen Biotech, INC. | $196.96 | 2025 | Tremfya, Simponi Aria, Simponi |
| Medtronic, INC. | $180.22 | 2024 | Linq II |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.92 | 2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $158.26 | 2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $157.67 | 2025 | Entyvio, Vpriv |
| Astrazeneca Pharmaceuticals Lp | $140.19 | 2023-2024 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $128.30 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $125.36 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $99.40 | 2023-2024 | Inpefa |
| Intercept Pharmaceuticals, INC. | $86.19 | 2025 | |
| Qol Medical, LLC | $80.85 | 2025 | Sucraid |
| Janssen Pharmaceuticals, INC | $75.94 | 2023-2024 | Xarelto |
| Esperion Therapeutics, INC. | $62.14 | 2023-2024 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $54.59 | 2024 | Arcalyst |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $52.55 | 2023-2024 | Lifevest |
| Ardelyx, INC. | $52.19 | 2025 | Ibsrela |
| Irhythm Technologies, INC. | $49.01 | 2022-2024 | Zio Xt Patch |
| Atricure, INC. | $33.73 | 2023 | |
| Gilead Sciences, INC. | $24.93 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $24.03 | 2024 | Camzyos |
| Inari Medical, INC. | $21.51 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $20.93 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Arbor Pharmaceuticals, INC. | $20.93 | 2022 | |
| Boston Scientific Corporation | $13.46 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Su listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.